Run the Experiment, Publish the Study, Close the Sale: Business, Values, Science and Biomedical Research – A Thematic Introduction


  • Aleta Quinn Smithsonian Institution, USA



Values, biomedical research, applied science, business, contract research organization


Business models for biomedical research prescribe decentralization due to market selection pressures. I argue that decentralized biomedical research does not match four normative philosophical models of the role of values in science. Non-epistemic values affect the internal stages of for-profit biomedical science. Publication planning, effected by Contract Research Organizations, inhibits mechanisms for transformative criticism. The structure of contracted research precludes attribution of responsibility for foreseeable harm resulting from methodological choices. The effectiveness of business strategies leads to over-representation of profit values versus the values of the general public. These disconnects in respect to the proper role of values in science results from structural issues ultimately linked to the distinct goals of business versus applied science, and so it seems likely that disconnects will also be found in other dimensions of attempts to combine business and science. The volume and integration in the publishing community of decentralized biomedical research imply that the entire community of biomedical research science cannot match the normative criteria of community-focused models of values in science. Several proposals for changing research funding structure might successfully relieve market pressures that drive decentralization.


Anderson, Monique L., Karen Chiswell, Eric D. Peterson, Asba Tasneem, James Topping, and Robert M. Califf. ‘Compliance with Results Reporting at Clinicaltrials.Gov’, NewEngland Journal of Medicine, 372:11 (2015), pp. 1031-1039. DOI: 10.1056/NEJMsa1409364

Azoulay, Pierre. ‘Capturing Knowledge within and across Firm Boundaries: Evidence from Clinical Development’, The American Economic Review, 94:5 (2004), pp. 1591-1612. DOI: 10.1257/0002828043052259

Bergsma, Jurrit, and David C. Thomasma. Autonomy and Clinical Medicine: Renewing theHealth Professional Relation with the Patient. Vol. 2. Springer Science & Business Media, 2000. DOI: 10.1007/978-94-017-0821-0

Brown, James Robert. ‘The Community of Science®’, in The Challenge of the Social and thePressure of Practice: Science and Values Revisited, edited by Martin Carrier, Don Howard and Janet A. Kourany, Pittsburgh: University of Pittsburgh Press, 2008, pp. 189-216.

Brown, Matthew J. ‘Values in Science Beyond Underdetermination and Inductive Risk’,Philosophy of Science, 80:5 (2013), pp. 829-839. DOI: 10.1086/673720

Carrier, Martin, and Patrick Finzer. ‘Theory and Therapy: On the Conceptual Structure of Models in Medical Research’, in Science in the Context of Application, edited by Martin Carrier and Alfred Nordmann (Springer, 2011), pp. 85-99. DOI: 10.1007/978-90-481-9051-5_6

Daniels, Norman. Just Health Care. New York, NY: Cambridge University Press, 1985. DOI: 10.1017/CBO9780511624971

Douglas, Heather. Science, Policy, and the Value-Free Ideal. Pittsburgh, PA: University of Pittsburgh Press, 2009.

Douglas, Heather. ‘The Moral Terrain of Science’, Erkenntnis, 79:5 (2014), pp. 961-979. DOI: 10.1007/s10670-013-9538-0

Elliott, Kevin Christopher. Is a Little Pollution Good for You? Incorporating Societal Values in Environmental Research. Oxford: Oxford University Press, 2010.

Envision Pharma. ‘Publications Planning’, planning/, 27 September 2008, online at (accessed

Envision Pharma. ‘Publications Planning’,, 31 March 2009, online at (accessed 2016-06-22).

Goldacre, Ben. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. New York: Faber & Faber, 2014.

Hansson, Sven Ove. ‘Values in Pure and Applied Science’, Foundations of Science, 12:3 (2007), pp. 257-268. DOI: 10.1007/s10699-007-9107-6

Healy, David. ‘Let Them Eat Prozac’, online at (accessed 2016-06-10).

Healy, David, and Dinah Cattell. ‘Interface between Authorship, Industry and Science in the Domain of Therapeutics’, The British Journal of Psychiatry 183:1 (2003), pp. 22-27. DOI: 10.1192/bjp.183.1.22

Horwitz, Allan V., and Jerome C. Wakefield. The Loss of Sadness: How PsychiatryTransformed Normal Sorrow into Depressive Disorder. Oxford: Oxford University Press, 2007.

International Committee of Medical Journal Editors. ‘Defining the Role of Authors and Contributors’, online at (accessed 2016-

Johnson, Ann. ‘Everything New Is Old Again: What Place Should Applied Science Have in the History of Science?’, in Science in the Context of Application, edited by Martin Carrier and Alfred Nordmann (Springer, 2011), pp. 455-466. DOI: 10.1007/978-90-481-9051-5_26

Kourany, Janet A. ‘Meeting the Challenges to Socially Responsible Science: Reply to Brown, Lacey, and Potter’, Philosophical Studies, 163:1 (2013), pp. 93-103. DOI: 10.1007/s11098-012-0073-7

Kukkar, Ankesh, Anjana Bali, Nirmal Singh, and Amteshwar Singh Jaggi. ‘Implications and Mechanism of Action of Gabapentin in Neuropathic Pain’, Archives of PharmacalResearch, 36:3 (2013), pp. 237-251. DOI: 10.1007/s12272-013-0057-y

Lexchin, Joel. ‘Clinical Trials in Canada: Whose Interests Are Paramount?’, InternationalJournal of Health Services, 38:3 (2008), pp. 525-542. DOI: 10.2190/HS.38.3.h

Longino, Helen E. Science as Social Knowledge: Values and Objectivity in Scientific Inquiry. Princeton, NJ: Princeton University Press, 1990.

Mack, Alicia. ‘Examination of the Evidence for Off-Label Use of Gabapentin’, Journal ofManaged Care Pharmacy, 9:6 (2003), pp. 559-568.

MacLaurin, James, and Kim Sterelny. What Is Biodiversity? Chicago, IL: University of Chicago Press, 2008. DOI: 10.7208/chicago/9780226500829.001.0001

Miller, Jennifer E., David Korn, and Joseph S. Ross. ‘Clinical Trial Registration, Reporting, Publication and FDAAA Compliance: A Cross-Sectional Analysis and Ranking of New Drugs Approved by the FDA in 2012’, BMJ Open, 5:11 (November 1, 2015), e009758.

Mirowski, Philip, and Robert Van Horn. ‘The Contract Research Organization and the Commercialization of Scientific Research’, Social Studies of Science, 35:4 (2005), pp. 503-548. DOI: 10.1177/0306312705052103

Nosek, B. A., G. Alter, G. C. Banks, D. Borsboom, S. D. Bowman, S. J. Breckler, S. Buck, et al. ‘Promoting an Open Research Culture’, Science, 348:6242 (2015), pp. 1422-1425. DOI: 10.1126/science.aab2374

Pisano, Gary. ‘Can Science Be a Business?’, Harvard Business Review 84:10 (2006), p. 114. Reiss, Julian. ‘In Favour of a Millian Proposal to Reform Biomedical Research’, Synthese, 177:3 (2010), pp. 427-447. DOI: 10.1007/s11229-010-9790-7

Reiss, Julian, and Philip Kitcher. ‘Biomedical Research, Neglected Diseases, and Well-Ordered Science’, Theoria, 24:3 (2009), pp. 263-282.

Scott, Amelia, Julia J. Rucklidge, and Roger T. Mulder. ‘Is Mandatory Prospective Trial Registration Working to Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration’, PloS one, 10:8 (2015), e0133718.

Sismondo, Sergio. ‘Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry?’, PLoS Medicine, 4:9 (2007), e286.

Sismondo, Sergio, and Scott Howard Nicholson. ‘Publication Planning 101’, Journal ofPharmacy & Pharmaceutical Sciences, 12:3 (2009), pp. 273-279.

Vedula, S. Swaroop, Tianjing Li, and Kay Dickersin. ‘Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin’, PLoSMedicine 10:1 (2013), e1001378.

World Health Organization. ‘WHO Constitution; 1948’, in Official Records of the World Health Organization, 2 (1948), pp. 100-109.




How to Cite

Quinn, A. (2016) “Run the Experiment, Publish the Study, Close the Sale: Business, Values, Science and Biomedical Research – A Thematic Introduction ”, De Ethica, 3(2), pp. 5–21. doi: 10.3384/de-ethica.2001-8819.16325.